These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 6517228)

  • 1. Spleen iron content is low in thalassemia.
    Borgna-Pignatti C; De Stefano P; Bongo IG; Avato F; Cazzola M
    Am J Pediatr Hematol Oncol; 1984; 6(3):340-3. PubMed ID: 6517228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron metabolism in thalassemia intermedia.
    Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C; Rachmilewitz EA
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nuclear magnetic resonance and iron overload in thalassemia].
    Schettini F; De Mattia D; Cavallo L; Sabato V; Santoro N; Del Vecchio GC; Martinelli G; Martinelli A; Di Bartolomeo P; Di Girolamo G
    Minerva Pediatr; 1991 Dec; 43(12):777-81. PubMed ID: 1798402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalassemia in Italy: treatment of Cooley disease and iron kinetics in heterozygotes.
    Rotoli B
    Birth Defects Orig Artic Ser; 1976; 12(8):53-61. PubMed ID: 1009235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.
    Mazza P; Giua R; De Marco S; Bonetti MG; Amurri B; Masi C; Lazzari G; Rizzo C; Cervellera M; Peluso A
    Haematologica; 1995; 80(5):398-404. PubMed ID: 8566878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.
    Musallam KM; Cappellini MD; Wood JC; Taher AT
    Blood Rev; 2012 Apr; 26 Suppl 1():S16-9. PubMed ID: 22631036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 11. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 12. Intensive transfusion therapy in thalassemia major.
    Beard ME; Necheles TF; Allen DM
    Pediatrics; 1967 Nov; 40(5):911-5. PubMed ID: 6075668
    [No Abstract]   [Full Text] [Related]  

  • 13. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common queries in thalassemia care.
    Panigrahi I; Marwaha RK
    Indian Pediatr; 2006 Jun; 43(6):513-8. PubMed ID: 16820660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of T2* magnetic resonance in monitoring iron chelation therapy.
    Carpenter JP; Pennell DJ
    Acta Haematol; 2009; 122(2-3):146-54. PubMed ID: 19907152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splenectomy, iron overload and liver cirrhosis in beta-thalassemia major.
    Okon E; Levij IS; Rachmilewitz EA
    Acta Haematol; 1976; 56(3):142-50. PubMed ID: 826069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary somatotropic and corticotropic function in patients with beta-thalassemia on iron chelation therapy.
    Tolis G; Politis C; Kontopoulou I; Poulatzas N; Rigas G; Saridakis C; Athanasiou V; Mortoglou A; Malachtari S; Ling N
    Birth Defects Orig Artic Ser; 1987; 23(5A):449-52. PubMed ID: 3120817
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

  • 20. Noninvasive analysis of skin iron and zinc levels in beta-thalassemia major and intermedia.
    Gorodetsky R; Goldfarb A; Dagan I; Rachmilewitz EA
    J Lab Clin Med; 1985 Jan; 105(1):44-51. PubMed ID: 3968464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.